Physician profile
Warda Riaz
NPI 1134744105
$7,541.97
in general payments reported to CMS, 2019-2025
20 companies · $929 in 2025
The $929 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $859 · 2021: $1,919 · 2022: $445 · 2023: $2,133 · 2024: $1,257 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140 · Entertainment: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,140.28 |
| Entertainment | $178.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,332.89 | 2021-2025 | Total30, Precision 1, Dailies Total1 |
| Bausch & Lomb Americas INC. | $977.99 | 2022-2025 | Miebo, Xiidra, Infuse |
| Coopervision INC. | $842.25 | 2020-2025 | Misight Contact Lens, Cvi Contact Lens, Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $759.47 | 2021-2024 | Acuvue |
| Glaukos Corporation | $700.79 | 2020-2025 | Idosetr |
| Abbvie INC. | $274.29 | 2023-2025 | |
| Allergan, INC. | $210.54 | 2021 | |
| Optos, INC. | $178.57 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $177.77 | 2021 | |
| Eyevance Pharmaceuticals LLC | $140.64 | 2021 | |
| Oyster Point Pharma, INC. | $137.36 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $135.99 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $129.36 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $125.00 | 2021 | |
| Astellas Pharma US INC | $121.85 | 2023 | Izervay |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $117.67 | 2020 | |
| Ocular Therapeutix, INC. | $62.50 | 2020 | |
| Biotissue Holdings INC. | $59.01 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $40.21 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $17.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warda Riaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.